The group given 6 months of trastuzumab also had lower rates of grade 3 or 4 cough, fatigue, pain, chills, and palpitations, problems which patients reported were having an impact on their lives, Dr. Earl noted. “Perhaps more importantly, patients given 6 months of treatment will be able to return more quickly to their normal lives once their treatment is completed.”
Dr. Earl disclosed that she has a consulting or advisory role with Celgene, Pfizer, Roche, and AstraZeneca; receives travel, accommodations, or expenses, and receives honoraria from Pfizer, Daiichi Sankyo, Amgen, and AstraZeneca; and receives research funding from Roche and Sanofi Pasteur. The study was funded by the National Institute for Health Research in the United Kingdom.
SOURCE: Earl H et al. ASCO 2018, Abstract 506.